GUD.TO has been in the news 1000% more than usual

GUD.TO has been in the news recently: Knight Therapeutics Inc. has secured exclusive licensing agreements to commercialize Sumitomo Pharma's products in Canada for C$25.4 million, which includes potential future payments of C$15.75 million. Additionally, Knight Therapeutics discussed its merger with Sumitomo Pharma America Holdings, Inc. during a conference call on June 5, 2025.